Head and Neck Squamous Cell Carcinoma
Clinical research in recurrent and metastatic head and neck squamous cell carcinoma focuses on treatment after immune checkpoint inhibitor failure, with attention to objective response rate and disease control in later-line settings.
- Recurrent/metastatic disease
- Post-immunotherapy treatment
- Combination systemic therapy
The therapeutic interest centers on integrating platinum-based chemotherapy, taxane therapy, and EGFR-targeted treatment in squamous cell carcinoma of the head and neck.
HER2-Positive Metastatic Breast Cancer
Research activity in metastatic breast cancer is concentrated on HER2-positive disease, with evaluation of treatment strategies designed to improve objective response rate alongside standard anti-HER2 therapy.
- HER2-targeted treatment
- Metastatic breast cancer
- Response-focused outcomes
The clinical focus includes targeted therapy in advanced breast cancer and the role of oral add-on treatment in combination with established anti-HER2 regimens.
Targeted Oncology Combinations
The sponsor’s trial portfolio reflects interest in combining cytotoxic chemotherapy with targeted agents across solid tumors, especially in settings where standard treatment options have limited activity.
- Chemotherapy combinations
- Targeted antibody-based therapy
- Advanced solid tumors
This includes work involving carboplatin, paclitaxel, and cetuximab in difficult-to-treat oncology populations.
